{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:41:43Z","timestamp":1793994103090,"version":"4.8.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.beha.2018.07.014","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T14:01:08Z","timestamp":1532354468000},"page":"209-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Management of relapsed\/refractory DLBCL"],"prefix":"10.1016","volume":"31","author":[{"given":"Cl\u00e9mentine","family":"Sarkozy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2018.07.014_bib1","article-title":"US lymphoid malignancy statistics by World Health Organization subtypes","volume":"2016","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"1 Suppl 2","key":"10.1016\/j.beha.2018.07.014_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/sonc.2002.30153","article-title":"Rituximab in the treatment of diffuse large B-Cell lymphomas","volume":"29","author":"Coiffier","year":"2002","journal-title":"Semin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2018.07.014_bib3","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.beha.2018.07.014_bib4","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2018.07.014_bib5","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol : Offic J Am Soc Clin Oncol"},{"issue":"6769","key":"10.1016\/j.beha.2018.07.014_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.beha.2018.07.014_bib7","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.beha.2018.07.014_bib8","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.beha.2018.07.014_bib9","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2018.07.014_bib10","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2018.07.014_bib11","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2018.07.014_bib12","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2018.07.014_bib13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-Cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2018.07.014_bib14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.beha.2018.07.014_bib15","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.07.014_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.014_bib17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.14813","article-title":"Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy","volume":"179","author":"Farooq","year":"2017","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.beha.2018.07.014_bib18","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2018.07.014_bib19","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00277-015-2467-z","article-title":"Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment","volume":"94","author":"Hitz","year":"2015","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.beha.2018.07.014_bib20","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2009.24.5860","article-title":"Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome","volume":"28","author":"Larouche","year":"2010","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.beha.2018.07.014_bib21","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.beha.2018.07.014_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.beha.2018.07.014_bib23","doi-asserted-by":"crossref","first-page":"51494","DOI":"10.18632\/oncotarget.9860","article-title":"Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones","volume":"7","author":"Melchardt","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.beha.2018.07.014_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.24584","article-title":"Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas","volume":"92","author":"Rizzo","year":"2017","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.beha.2018.07.014_bib25","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","article-title":"Genetic landscapes of relapsed and refractory diffuse large B-Cell lymphomas","volume":"22","author":"Morin","year":"2016","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.beha.2018.07.014_bib26","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood.V77.7.1587.1587","article-title":"PARMA international protocol : pilot study of DHAP followed by involved field radiotherapy and BEAC with autologous bone marrow transplantation","volume":"77","author":"Philip","year":"1991","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.beha.2018.07.014_bib27","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.beha.2018.07.014_bib28","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2018.07.014_bib29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00277-017-2981-2","article-title":"Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+\/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas","volume":"96","author":"Tessoulin","year":"2017","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.014_bib30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3816\/CLML.2010.n.055","article-title":"Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"10","author":"Lignon","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.beha.2018.07.014_bib31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2001.03181.x","article-title":"An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma","volume":"115","author":"Chau","year":"2001","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2018.07.014_bib32","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3109\/10428194.2010.491137","article-title":"Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium","volume":"51","author":"Gopal","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.beha.2018.07.014_bib33","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2018.07.014_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-006-0210-5","article-title":"Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma","volume":"86","author":"Sieniawski","year":"2007","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.014_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/10428194.2016.1187274","article-title":"Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup\/>","volume":"58","author":"Baetz","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.beha.2018.07.014_bib36","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/annonc\/mdx556","article-title":"Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial","volume":"28","author":"Glass","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.beha.2018.07.014_bib37","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3324\/haematol.13440","article-title":"R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study","volume":"93","author":"Martin","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.beha.2018.07.014_bib38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","article-title":"Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial","volume":"111","author":"Vellenga","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2018.07.014_bib39","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-Cell lymphoma: the ORCHARRD study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.beha.2018.07.014_bib40","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.beha.2018.07.014_bib41","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-Cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol : Offic J Am Soc Clin Oncol"},{"issue":"19","key":"10.1016\/j.beha.2018.07.014_bib42","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2007.14.4204","article-title":"Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey","volume":"26","author":"Tarella","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2018.07.014_bib43","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2005.08.012","article-title":"Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-Cell non-Hodgkin's lymphomas","volume":"23","author":"Khouri","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.014_bib44","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.14731","article-title":"A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results","volume":"178","author":"Srour","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2018.07.014_bib45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","article-title":"Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","volume":"103","author":"Horwitz","year":"2004","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2018.07.014_bib46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood.V122.21.155.155","article-title":"A randomized trial of rituximab vs observation following autologous stem cell transplantation (ASCT) for relapsed or refractory CD20-positive B cell lymphoma: final results of NCIC CTG LY.12","volume":"122","author":"Michael Crump","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2018.07.014_bib47","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1158\/1078-0432.CCR-17-3561","article-title":"Updated results of rituximab pre- and post-beam with or without 90Yttrium-ibritumomab tiuxetan during autologous transplant for diffuse large B-Cell lymphoma","volume":"24","author":"Chahoud","year":"2018","journal-title":"Clin Canc Res"},{"issue":"13","key":"10.1016\/j.beha.2018.07.014_bib48","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"Vose","year":"2013","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.beha.2018.07.014_bib49","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2012-01-406033","article-title":"MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation","volume":"119","author":"Cuccuini","year":"2012","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.beha.2018.07.014_bib50","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.014_bib51","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjh.14453","article-title":"Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era","volume":"176","author":"Vardhana","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2018.07.014_bib52","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","article-title":"Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation","volume":"20","author":"Hamadani","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.beha.2018.07.014_bib53","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbmt.2011.10.010","article-title":"High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry","volume":"18","author":"Mounier","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2018.07.014_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2010.08162.x","article-title":"Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy","volume":"150","author":"Dickinson","year":"2010","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.beha.2018.07.014_bib55","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.07.014_bib56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2018.07.014_bib57","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2141.2005.05603.x","article-title":"Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens","volume":"130","author":"Ardeshna","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2018.07.014_bib58","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2018.07.014_bib59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbmt.2007.11.013","article-title":"Salvage therapy for relapsed\/refractory diffuse large B cell lymphoma","volume":"14","author":"Seshadri","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2018.07.014_bib60","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2016.04.019","article-title":"Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-hodgkin lymphoma: increasingly successful application to older patients","volume":"22","author":"Fenske","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2018.07.014_bib61","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bmt.2015.286","article-title":"Autologous stem cell transplantation for relapsed\/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party","volume":"51","author":"Robinson","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2018.07.014_bib62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2018.07.014_bib63","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2018.07.014_bib64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","article-title":"Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"16","author":"Sirvent","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.beha.2018.07.014_bib65","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2018.07.014_bib66","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2018.07.014_bib67","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/annonc\/mdw653","article-title":"Treatment outcomes for older patients with relapsed\/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial","volume":"28","author":"Davison","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.beha.2018.07.014_bib68","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3109\/10428194.2015.1106532","article-title":"Reduced-dose ICE chemotherapy +\/- rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma","volume":"57","author":"Sarid","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"10.1016\/j.beha.2018.07.014_bib69","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2018.07.014_bib70","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial","volume":"98","author":"Mounier","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2018.07.014_bib71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/0973-1482.63572","article-title":"Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria","volume":"6","author":"Aribi","year":"2010","journal-title":"J Canc Res Therapeut"},{"issue":"8","key":"10.1016\/j.beha.2018.07.014_bib72","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3109\/10428194.2015.1106536","article-title":"Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study","volume":"57","author":"Arcari","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.beha.2018.07.014_bib73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ejh.12416","article-title":"Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma","volume":"94","author":"Barton","year":"2015","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2018.07.014_bib74","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","article-title":"Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial","volume":"13","author":"Pettengell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.beha.2018.07.014_bib75","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjh.14021","article-title":"Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma","volume":"173","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.beha.2018.07.014_bib76","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2018.07.014_bib77","first-page":"581","article-title":"High durable CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (transcend NHL 001): defined composition allows for dose-finding and definition of pivotal cohort","volume":"130","author":"Abramson","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2018.07.014_bib78","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-Cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2018.07.014_bib79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"10.1016\/j.beha.2018.07.014_bib80","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus Investigator's choice in patients with relapsed or refractory diffuse large B-Cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Canc Res : Offic J Am Assoc Canc Res"},{"issue":"23","key":"10.1016\/j.beha.2018.07.014_bib81","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol : Offic J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2018.07.014_bib82","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol : Offic J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2018.07.014_bib83","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2018.07.014_bib84","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2018.07.014_bib85","first-page":"2821","article-title":"Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed\/refractory (R\/R) diffuse large B-Cell lymphoma (DLBCL) versus BR alone: results from a randomized phase 2 study","volume":"130","author":"Sehn","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.07.014_bib86","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.beha.2018.07.014_bib87","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2017-08-802561","article-title":"A phase I study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL","volume":"131","author":"Sauter","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.07.014_bib88","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol : Offic J Am Soc Clin Oncol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T19:44:18Z","timestamp":1751744658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618300562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1521692618300562"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.014","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of relapsed\/refractory DLBCL","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}